{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:16:42Z","timestamp":1794064602160,"version":"4.8.0"},"reference-count":272,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["SFB F73 [F7301"],"award-info":[{"award-number":["SFB F73 [F7301"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["SFB F70"],"award-info":[{"award-number":["SFB F70"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012623","name":"Federation of European Biochemical Societies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101117175"],"award-info":[{"award-number":["101117175"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jhep.2024.09.032","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:10:25Z","timestamp":1727536225000},"page":"134-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":262,"title":["Bile acid metabolism and signalling in liver disease"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-1320","authenticated-orcid":false,"given":"Claudia D.","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-0233","authenticated-orcid":false,"given":"Maximillian","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-0318","authenticated-orcid":false,"given":"Clarissa","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.09.032_bib1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular physiology of bile acid signaling in health, disease, and aging","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jhep.2024.09.032_bib5","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2017.01.014","article-title":"Farnesoid X receptor activation promotes hepatic amino acid catabolism and ammonium clearance in mice","volume":"152","author":"Massafra","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2010.12.004","article-title":"The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation","volume":"54","author":"Pols","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj0146","article-title":"Discoveries of GPR39 as an evolutionarily conserved receptor for bile acids and of its involvement in biliary acute pancreatitis","volume":"10","author":"Zi","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhep.2024.09.032_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1194\/jlr.R054114","article-title":"Intestinal transport and metabolism of bile acids","volume":"56","author":"Dawson","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.25992","article-title":"\u03b15 \u03b21-integrins are sensors for tauroursodeoxycholic acid in hepatocytes","volume":"57","author":"Gohlke","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/9781119436812.ch25","article-title":"Bile acids as signaling molecules","author":"Claudel","year":"2020","journal-title":"The Liver"},{"key":"10.1016\/j.jhep.2024.09.032_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1194\/jlr.R900007-JLR200","article-title":"Bile acids as regulatory molecules","volume":"50","author":"Hylemon","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.steroids.2014.04.016","article-title":"Bile acids are nutrient signaling hormones","volume":"86","author":"Zhou","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.jhep.2024.09.032_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jhep.2024.09.032_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2024.09.032_bib16","doi-asserted-by":"crossref","first-page":"22980","DOI":"10.1074\/jbc.M303415200","article-title":"Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover","volume":"278","author":"Lund","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/mol.112.080036","article-title":"Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines","volume":"82","author":"Scheer","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2024.09.032_bib18","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Honda","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100261","article-title":"Ileal bile acid transporter inhibition in Cyp2c70 KO mice ameliorates cholestatic liver injury","volume":"63","author":"Truong","year":"2022","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A\u00a0human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice","volume":"61","author":"de Boer","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmgh.2020.12.004","article-title":"Cholangiopathy and biliary fibrosis in Cyp2c70-deficient mice are fully reversed by ursodeoxycholic acid","volume":"11","author":"de Boer","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib23","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.cell.2023.07.017","article-title":"Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions","volume":"186","author":"Kaffe","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2024.09.032_bib24","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2009.05.012","article-title":"New molecular insights into the mechanisms of cholestasis","volume":"51","author":"Wagner","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2024.09.032_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda","year":"2003","journal-title":"Mol Endocrinol (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib28","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2024.09.032_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1210\/en.2004-0965","article-title":"Regulation of carbohydrate metabolism by the farnesoid X receptor","volume":"146","author":"Stayrook","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.jhep.2024.09.032_bib31","doi-asserted-by":"crossref","first-page":"23158","DOI":"10.1074\/jbc.M314322200","article-title":"Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1","volume":"279","author":"Yamagata","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib32","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2024.09.032_bib33","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2024.09.032_bib34","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jhep.2024.09.032_bib35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2024.09.032_bib36","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1073\/pnas.0600780103","article-title":"How bile acids confer gut mucosal protection against bacteria","volume":"103","author":"Hofmann","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2024.09.032_bib37","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2024.09.032_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40168-019-0628-3","article-title":"Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome","volume":"7","author":"Song","year":"2019","journal-title":"Microbiome"},{"key":"10.1016\/j.jhep.2024.09.032_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/science.abp9960","article-title":"The microbiome and gut homeostasis","volume":"377","author":"Lee","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jhep.2024.09.032_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cell.2021.12.035","article-title":"Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome","volume":"185","author":"Jin","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2024.09.032_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0022-2275(20)41624-4","article-title":"A\u00a0proposed nomenclature for bile acids","volume":"33","author":"Hofmann","year":"1992","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib43","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.3390\/ijms13078882","article-title":"Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode","volume":"13","author":"Kotb","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2024.09.032_bib44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.23631","article-title":"Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression","volume":"52","author":"Sinakos","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1152\/ajpgi.00027.2007","article-title":"Human cecal bile acids: concentration and spectrum","volume":"293","author":"Hamilton","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib46","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nchembio.1864","article-title":"A biosynthetic pathway for a prominent class of microbiota-derived bile acids","volume":"11","author":"Devlin","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jhep.2024.09.032_bib47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2019.03.008","article-title":"Intestinal bile acids induce a morphotype switch in vancomycin-resistant Enterococcus that facilitates intestinal colonization","volume":"25","author":"McKenney","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jhep.2024.09.032_bib48","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.09.032_bib49","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep.31652","article-title":"Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation","volume":"74","author":"Mousa","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib52","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/mc.22999","article-title":"Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis","volume":"58","author":"Wang","year":"2019","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.jhep.2024.09.032_bib53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.1965","article-title":"Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development","volume":"8","author":"Pearson","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the\u00a0microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41586-023-05989-7","article-title":"Profiling the human intestinal environment under physiological conditions","volume":"617","author":"Shalon","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib56","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000383","article-title":"Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR","volume":"8","author":"Ay","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib57","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.cell.2024.02.019","article-title":"The underappreciated diversity of bile acid modifications","volume":"187","author":"Mohanty","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2024.09.032_bib58","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control T(H)17 and T(reg) cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","article-title":"Human gut bacteria produce T\u039717-modulating bile acid metabolites","volume":"603","author":"Paik","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","article-title":"Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells","volume":"581","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib62","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2024.09.032_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi4354","article-title":"Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis","volume":"14","author":"Shi","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib64","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054472","article-title":"The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation","volume":"8","author":"Renga","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.09.032_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41586-021-03421-6","article-title":"CAR directs T cell adaptation to bile acids in the small intestine","volume":"593","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib67","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A\u00a0G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and function of the bile acid receptor TGR5 in Kupffer cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem biophysical Res Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem biophysical Res Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib70","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41385-019-0162-4","article-title":"Emerging roles of bile acids in mucosal immunity and inflammation","volume":"12","author":"Chen","year":"2019","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jhep.2024.09.032_bib71","doi-asserted-by":"crossref","first-page":"21805","DOI":"10.1074\/jbc.C000275200","article-title":"Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alpha-hydroxylase","volume":"275","author":"Miyake","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib72","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.ajpath.2016.06.003","article-title":"Pathogenesis of kupffer cells in cholestatic liver injury","volume":"186","author":"Sato","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2024.09.032_bib73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.taap.2009.11.013","article-title":"Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling","volume":"243","author":"Allen","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jhep.2024.09.032_bib74","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ajpath.2013.07.019","article-title":"IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis","volume":"183","author":"O\u2019Brien","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2024.09.032_bib75","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/hep4.1998","article-title":"Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(-\/-) mouse model of sclerosing cholangitis via immunomodulatory effects","volume":"6","author":"Fuchs","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib76","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib77","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.tiv.2012.12.020","article-title":"Bile acids in the colon, from healthy to cytotoxic molecules","volume":"27","author":"Barrasa","year":"2013","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.jhep.2024.09.032_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jhep.2020.04.036","article-title":"Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults","volume":"73","author":"Stattermayer","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib79","doi-asserted-by":"crossref","first-page":"G923","DOI":"10.1152\/ajpgi.00490.2005","article-title":"Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha\/beta in the adaptive response to bile acids","volume":"290","author":"Zollner","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib80","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0168-8278(03)00228-9","article-title":"Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine","volume":"39","author":"Zollner","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib81","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib82","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A\u00a0regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2024.09.032_bib83","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.22627","article-title":"Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression","volume":"49","author":"Song","year":"2009","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib84","article-title":"Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis","volume":"4","author":"Braadland","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2021.02.011","article-title":"Bile formation and secretion: an update","volume":"75","author":"Boyer","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib87","doi-asserted-by":"crossref","first-page":"16390","DOI":"10.1074\/jbc.M000953200","article-title":"The acute phase response is associated with retinoid X receptor repression in rodent liver","volume":"275","author":"Beigneux","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-2000-9386","article-title":"Short-term regulation of canalicular transport","volume":"20","author":"Haussinger","year":"2000","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2024.09.032_bib89","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/2101262a0","article-title":"Cholestasis in rats induced by taurolithocholate","volume":"210","author":"Javitt","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib90","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.M209898200","article-title":"Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets","volume":"278","author":"Beuers","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000450915","article-title":"Mechanisms of tauroursodeoxycholate-mediated hepatoprotection","volume":"35","author":"Haussinger","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2024.09.032_bib92","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib94","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jhep.2016.09.020","article-title":"The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation","volume":"66","author":"Schrumpf","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib95","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.27927","article-title":"Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib96","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","author":"Schneider","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2024.09.032_bib97","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1038\/s41467-023-38840-8","article-title":"Colitis ameliorates cholestatic liver\u00a0disease via suppression of bile acid synthesis","volume":"14","author":"Gui","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib98","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib99","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hep.31140","article-title":"Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary sclerosing cholangitis (PSC)","volume":"72","author":"Kunzmann","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib100","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/gutjnl-2023-330856","article-title":"Protective function of sclerosing cholangitis on IBD","volume":"73","author":"Bedke","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib101","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gutjnl-2019-318416","article-title":"Alterations of the bile microbiome in primary sclerosing cholangitis","volume":"69","author":"Liwinski","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib102","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib104","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib106","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib107","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib108","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib109","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib111","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib112","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib113","first-page":"31A","article-title":"The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo-controlled trial","volume":"70","author":"Kowdley","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12876-023-02653-2","article-title":"PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis","volume":"23","author":"Trauner","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"S1","key":"10.1016\/j.jhep.2024.09.032_bib115","first-page":"1","article-title":"A\u00a0phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)","volume":"78","author":"Trauner","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib116","article-title":"Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-\/-) mouse model of sclerosing cholangitis","volume":"5","author":"Fuchs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib117","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib118","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib119","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1073\/pnas.1009427107","article-title":"Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)","volume":"107","author":"Wu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2024.09.032_bib120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35496-z","article-title":"Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from fibrosis and hepatocarcinogenesis","volume":"8","author":"Gadaleta","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib122","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib123","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib124","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib125","doi-asserted-by":"crossref","first-page":"G371","DOI":"10.1152\/ajpgi.00400.2012","article-title":"Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice","volume":"304","author":"Potthoff","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.gastro.2007.04.007","article-title":"Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis","volume":"133","author":"Marzioni","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib127","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/gut.2008.150870","article-title":"Exendin-4, a glucagon-like peptide\u00a01\u00a0receptor agonist, protects cholangiocytes from apoptosis","volume":"58","author":"Marzioni","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib128","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib129","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2024.09.032_bib131","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib132","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2024.09.032_bib133","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib134","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000153","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: open-label pilot study","volume":"7","author":"Bowlus","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A\u00a0randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib136","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/HEP.0000000000000376","article-title":"A3907, a systemic\u00a0ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans","volume":"78","author":"Caballero-Camino","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib137","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12072-016-9718-5","article-title":"Hepatitis B virus receptors and molecular drug targets","volume":"10","author":"Verrier","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.09.032_bib138","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.29888","article-title":"Na(+) -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice","volume":"68","author":"Slijepcevic","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib139","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/gutjnl-2020-323345","article-title":"Sodium(+)\/taurocholate cotransporting polypeptide as target therapy for liver fibrosis","volume":"71","author":"Salhab","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib140","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1136\/gutjnl-2021-326452","article-title":"Insufficient evidence for NTCP activity in stellate cells","volume":"71","author":"Kunst","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib141","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.01.007","article-title":"Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor","volume":"128","author":"Svegliati-Baroni","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib142","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.08.017","article-title":"Metabolic preconditioning protects BSEP\/ABCB11(-\/-) mice against cholestatic liver injury","volume":"66","author":"Fuchs","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib143","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0016-5085(86)90859-0","article-title":"Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents","volume":"90","author":"Yoon","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib144","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib145","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hep.29804","article-title":"Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl(-) channels","volume":"68","author":"Li","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib147","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","article-title":"Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis","volume":"75","author":"Reich","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib148","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation","volume":"75","author":"Zhu","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib149","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"Halilbasic","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2024.09.032_bib150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib151","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)01064-4","article-title":"Norucholic acid for the treatment of primary sclerosing cholangitis: baseline data from a phase III trial","volume":"78","author":"Trauner","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib153","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1053\/j.gastro.2012.02.033","article-title":"Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies","volume":"142","author":"Debray","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib154","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/j.gastro.2012.04.036","article-title":"A\u00a0cholecystohepatic shunt pathway: does the gallbladder protect the liver?","volume":"142","author":"Boyer","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib155","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/me.2010-0460","article-title":"The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling","volume":"25","author":"Li","year":"2011","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jhep.2024.09.032_bib156","article-title":"TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload","volume":"3","author":"Bidault-Jourdainne","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib157","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1669940","article-title":"Role of TGR5 (GPBAR1) in liver disease","volume":"38","author":"Keitel","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2024.09.032_bib158","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in\u00a0vivo and in\u00a0vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib159","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12016-014-8443-x","article-title":"TGR5: pathogenetic role and\/or therapeutic target in fibrosing cholangitis?","volume":"48","author":"Keitel","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2024.09.032_bib160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib161","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib162","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.26225","article-title":"Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis","volume":"57","author":"Bechmann","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib163","article-title":"NASH-related increases in plasma bile acid levels depend on insulin resistance","volume":"3","author":"Grzych","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib164","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2024.09.032_bib165","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1210\/jc.2017-01397","article-title":"Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects","volume":"102","author":"Legry","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2024.09.032_bib166","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jhep.2024.09.032_bib167","doi-asserted-by":"crossref","first-page":"G440","DOI":"10.1152\/ajpgi.00322.2009","article-title":"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance","volume":"298","author":"Schreuder","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib168","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-020-19803-9","article-title":"Intestinal FGF15\/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib169","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41591-019-0660-7","article-title":"Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression","volume":"25","author":"Segovia-Miranda","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11745-009-3300-z","article-title":"Chiorean E.,et al.Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls","volume":"44","author":"Acalovschi","year":"2009","journal-title":"Lipids"},{"key":"10.1016\/j.jhep.2024.09.032_bib171","doi-asserted-by":"crossref","first-page":"24784","DOI":"10.1074\/jbc.M111.329318","article-title":"Abcb11 deficiency induces cholestasis coupled to impaired beta-fatty acid oxidation in mice","volume":"287","author":"Zhang","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib172","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/liv.14423","article-title":"Absence of Bsep\/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice","volume":"40","author":"Fuchs","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.09.032_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234750","article-title":"Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet","volume":"15","author":"Okushin","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.09.032_bib174","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.09.032_bib176","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2024.09.032_bib177","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2022.01.069","article-title":"Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor","volume":"595","author":"Jiang","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib179","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib180","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib181","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib182","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib183","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A\u00a0structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib184","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib185","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change\u00a0in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib186","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib187","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.09.032_bib188","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib189","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib191","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib192","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib193","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2024.09.032_bib194","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.09.032_bib195","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib196","article-title":"24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARgamma","volume":"5","author":"Grander","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib197","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf4823","article-title":"Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice","volume":"8","author":"Rao","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib198","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib199","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","article-title":"Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders","volume":"14","author":"Karpen","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.09.032_bib200","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","article-title":"Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice","volume":"295","author":"Takahashi","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib201","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial","volume":"56","author":"Le","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib202","article-title":"NTCP deficiency in mice protects against obesity and hepatosteatosis","volume":"5","author":"Donkers","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2024.09.032_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110053","article-title":"Hepalatide ameliorated progression of nonalcoholic steatohepatitis in mice","volume":"126","author":"Liu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jhep.2024.09.032_bib204","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/hep.30824","article-title":"Liver injury and failure in critical illness","volume":"70","author":"Horvatits","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib205","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1046\/j.1440-1746.1999.01982.x","article-title":"Inflammation-induced cholestasis","volume":"14","author":"Trauner","year":"1999","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib206","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ncpgasthep0602","article-title":"Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis","volume":"3","author":"Geier","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib207","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1074\/jbc.275.12.8835","article-title":"Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation","volume":"275","author":"Denson","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2024.09.032_bib208","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1172\/JCI1680","article-title":"Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors","volume":"101","author":"Trauner","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2024.09.032_bib209","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41423-023-01026-9","article-title":"Emerging roles of bile acids in chronic hepatitis, liver\u00a0cirrhosis, and hepatocellular carcinoma","volume":"20","author":"Xun","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2024.09.032_bib210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1440-1746.2000.02126.x","article-title":"Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment","volume":"15","author":"Shima","year":"2000","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib211","article-title":"Prognostic significance of elevated cholestatic enzymes for fibrosis and hepatocellular carcinoma in hospital discharged chronic viral hepatitis patients","volume":"7","author":"Xie","year":"2017","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib212","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2893.2012.01628.x","article-title":"Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C","volume":"20","author":"Shlomai","year":"2013","journal-title":"J\u00a0viral Hepat"},{"key":"10.1016\/j.jhep.2024.09.032_bib213","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"3","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.jhep.2024.09.032_bib214","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hep.26181","article-title":"Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes","volume":"58","author":"Meier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A\u00a0targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib216","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2015-310686","article-title":"The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B","volume":"65","author":"Hu","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib217","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.27240","article-title":"Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype","volume":"61","author":"Vaz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib218","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2014.05.018","article-title":"Kinetics of the bile acid transporter and hepatitis B virus receptor Na+\/taurocholate cotransporting polypeptide (NTCP) in hepatocytes","volume":"61","author":"Konig","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib219","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A\u00a0phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib221","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \"real world\" study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.09.032_bib222","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.3748\/wjg.v25.i39.5897","article-title":"Gut-liver axis signaling in portal hypertension","volume":"25","author":"Simbrunner","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.09.032_bib223","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2024.09.032_bib224","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","article-title":"Gut-liver axis: barriers and functional circuits","volume":"20","author":"Pabst","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib225","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/apt.16602","article-title":"Therapeutic aspects of bile acid signalling in the gut-liver axis","volume":"54","author":"Simbrunner","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.09.032_bib226","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib227","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib228","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib229","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010060","article-title":"The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2024.09.032_bib230","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2024.09.032_bib231","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib232","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2023.11.001","article-title":"Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module","volume":"80","author":"Bendixen","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib233","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1053\/jhep.2003.50116","article-title":"Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats","volume":"37","author":"Lorenzo-Zuniga","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib234","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2024.09.032_bib235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.09.032_bib236","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","article-title":"Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats","volume":"64","author":"Ubeda","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib237","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2019.06.017","article-title":"FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis","volume":"71","author":"Sorribas","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib238","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s12072-023-10636-4","article-title":"FXR-FGF19 signaling in the gut\u2013liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence","volume":"18","author":"Simbrunner","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.09.032_bib239","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis","volume":"5","author":"John","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.09.032_bib240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.12703\/r\/10-48","article-title":"Recent advances in the understanding and management of hepatorenal syndrome","volume":"10","author":"Simbrunner","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.jhep.2024.09.032_bib241","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2023.10.035","article-title":"Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis","volume":"80","author":"Ghallab","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib242","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/hep.26599","article-title":"Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice","volume":"58","author":"Fickert","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib243","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib244","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1111\/liv.15413","article-title":"Natural history, spectrum and outcome of stage 3 AKI in patients with acute-on-chronic liver failure","volume":"42","author":"Maiwall","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.09.032_bib245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.chom.2022.02.004","article-title":"Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis","volume":"30","author":"Cai","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jhep.2024.09.032_bib246","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.23539","article-title":"ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history","volume":"51","author":"Davit-Spraul","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.09.032_bib247","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.30219","article-title":"Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis","volume":"139","author":"Xie","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2024.09.032_bib248","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.09.032_bib249","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1121435","article-title":"Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration","volume":"312","author":"Huang","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jhep.2024.09.032_bib250","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhep.2024.09.032_bib251","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11549-7","article-title":"Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-\/-) mice","volume":"7","author":"Cariello","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.09.032_bib252","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A\u00a0mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2024.09.032_bib253","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.09.032_bib254","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A\u00a0first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/hep-2017-0008","article-title":"Fibroblast growth factor 19, a double-edged sword","volume":"4","author":"Jansen","year":"2017","journal-title":"Hepat Oncol"},{"key":"10.1016\/j.jhep.2024.09.032_bib256","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jhep.2024.09.032_bib257","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib258","doi-asserted-by":"crossref","first-page":"G31","DOI":"10.1152\/ajpgi.00536.2002","article-title":"Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines","volume":"285","author":"Werneburg","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2024.09.032_bib259","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2024.09.032_bib260","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/1061186021000001841","article-title":"Relationship between tumor cell load and sensitivity to the cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2","volume":"10","author":"Larena","year":"2002","journal-title":"J Drug Target"},{"key":"10.1016\/j.jhep.2024.09.032_bib261","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.08.022","article-title":"Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)","volume":"216","author":"Lozano","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.jhep.2024.09.032_bib262","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.molmed.2011.05.010","article-title":"Bile acids and colon cancer: solving the puzzle with nuclear receptors","volume":"17","author":"Degirolamo","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2024.09.032_bib263","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.09.032_bib264","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.bcp.2005.07.023","article-title":"Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors","volume":"70","author":"Cheng","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2024.09.032_bib265","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1023\/B:DDAS.0000034558.78747.98","article-title":"The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer","volume":"49","author":"De Gottardi","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2024.09.032_bib266","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2009.09.060","article-title":"The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors","volume":"138","author":"Modica","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.09.032_bib267","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1158\/0008-5472.CAN-08-1791","article-title":"Nuclear bile acid receptor FXR protects against intestinal tumorigenesis","volume":"68","author":"Modica","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2024.09.032_bib268","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/carcin\/bgq050","article-title":"Sodium taurocholate inhibits intestinal adenoma formation in APCMin\/+ mice, potentially through activation of the farnesoid X receptor","volume":"31","author":"Smith","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhep.2024.09.032_bib269","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048461","article-title":"Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis","volume":"7","author":"Peng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.09.032_bib270","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","article-title":"FXR regulates intestinal cancer stem cell proliferation","volume":"176","author":"Fu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2024.09.032_bib271","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/ijc.26293","article-title":"Expression of the nuclear bile acid receptor\/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be\u00a0associated with adverse prognosis","volume":"130","author":"Lax","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2024.09.032_bib272","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00018-022-04278-2","article-title":"The role of bile acids in carcinogenesis","volume":"79","author":"Rezen","year":"2022","journal-title":"Cell Mol Life Sci"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824025728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824025728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:58:54Z","timestamp":1773457134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824025728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":272,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0168827824025728"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.09.032","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acid metabolism and signalling in liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}